1. Immunology/Inflammation
  2. CD19

CD19

 

CD19 Related Products (14):

Cat. No. Product Name Effect Purity
  • HY-153084
    CD19 CAR mRNA
    CD19 CAR mRNA will express CD19 car protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
  • HY-P99113
    Inebilizumab Inhibitor
    Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research[1].
  • HY-P9963
    Blinatumomab 98.78%
    Blinatumomab (Anatumomab) is a bispecific monoclonal antibody which can specifically targets the CD19 antigen present on B cells. Blinatumomab can be used for the research of acute lymphoblastic leukemia[1].
  • HY-P99285
    Denintuzumab Inhibitor
    Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia[1].
  • HY-P99711
    Loncastuximab Inhibitor
    Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL)[1][2].
  • HY-153233
    CD19 car mRNA-LNP
    CD19 car mRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car mRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car mRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction[1][2].
  • HY-P990017
    Englumafusp alfa Inhibitor
    Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells[1].
  • HY-153085
    CD19 CAR circRNA
    CD19 CAR circRNA will express CD19 car protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
  • HY-P99577
    Taplitumomab paptox
    Taplitumomab paptox is an anti-CD19 monoclonal antibody. Taplitumomab paptox can be used in cancer research.
  • HY-P99761
    Obexelimab
    Obexelimab (XmAb5871) is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcγRIIb. Obexelimab can be used in research of autoimmune[1].
  • HY-153234
    CD19 car circRNA-LNP
    CD19 car circRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car circRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car circRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction[1][2].
  • HY-P99338
    Tisagenlecleucel
    Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma[1][2].
  • HY-P99868
    Duvortuxizumab
    Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E[1].
  • HY-P99976
    Anti-Mouse CD19 Antibody (1D3) Inhibitor
    Anti-Mouse CD19 Antibody (1D3) is an anti-mouse CD19 IgG2a antibody inhibitor.